Psychiatr. praxi 2017; 18(1): 7-10 | DOI: 10.36290/psy.2017.002

Research of new drugs for Alzheimer’s disease

PharmDr. Jana Hroudová, Ph.D.

Psychiatrická klinika, 1. lékařská fakulta, Univerzita Karlova a VFN v Praze, Farmakologický ústav, 1. lékařská fakulta, Univerzita Karlova a VFN v Praze, Oddělení klinické farmakologie, VFN v Praze

Alzheimer’s disease (AD) is the most common cause of dementia, however, the treatment AD options are limited and based on

administration of cholinesterase inhibitors and/or memantine, affecting glutamatergic system. Presented review article summarizes

current approaches in the research of novel agents for AD treatment; it is focused on the molecules reaching the clinical trials.

The most developed direction of pharmacotherapy is focused on pathologic β-amyloid (Aβ). Several perspective studies testing

monoclonal Aβ antibodies and β-secretase inhibitors are ongoing. Further, new cholinesterase inhibitors, monoamine oxidase

inhibitors, anti-tau immunotherapy, agents affecting serotonin and nicotine receptors, antioxidants, and others are developed.

Keywords: Alzheimer’s disease, cholinesterase inhibitors, anti-amyloid beta immunotherapy, beta secretase inhibitors, monoamine oxidase inhibitors

Published: May 1, 2017  Show citation